Lilly, which has been active in the fight against diabetes for more than 100 years, has announced a new commitment with tirzepatide, an innovative therapy for type 2 diabetes.
This new solution is the result of decades of metabolic research and is available at all pharmacies open to the public, upon prescription from your general practitioner or specialist. Tirzepatide represents the first drug in a new class, a dual agonist of the GIP and GLP-1 receptors, capable of acting not only on the control of glycated hemoglobin, but also on weight, with an enhanced effect.
Investment in Italy
Federico Villa, Associate Vice President Corporate Affairs & Patient Access Lilly Italy Hub, declared in his speech in Rome, during the press conference entitled 'Type 2 diabetes: investing in health, between access to innovation and efficiency of the NHS, is the challenge for the future', that "we are proud to produce it in our plant in Sesto Fiorentino, also through an expansion that has guaranteed an investment in Italy of approximately one billion euros, a product that is exported to over 70 countries in the world".
The innovative therapy was recently made reimbursable by the Italian Medicines Agency (AIFA), representing a significant step forward in access to diabetes treatments.
Verified Source
Comments (1)
I feel that this new therapy tirzepatide is very important for those with type 2 diabetes. However, I wonder if there will be side effects and how will the access to the therapy be for everyone, especially for older people who have difficulty finding a doctor.